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Long-term Results of Radiotherapy in Patients with 
Chronic Palmo-plantar Eczema or Psoriasis 
Marcin Sumila1, Markus Notter1, Peter Itin2, Stephan Bodis1, Guenther Gruber1 
Background and Purpose: Radiotherapy (RT) is well accepted for therapy-refractory palmo-plantar eczema or psoriasis, despite 
of lacking evidence regarding beneficial long term effects. Furthermore, the optimal irradiation dose is unknown. We evaluated 
the outcome of RT with two different RT single/total dose (SD/TD) treatment policies. 
Patients and Methods: 28 consecutive patients with therapy-refractory eczema (n = 22) or psoriasis (n = 6) of palms and/or 
soles were irradiated twice a week either with a Dmax SD of 1 Gy (6/98–5/03; median TD: 12 Gy) or 0.5 Gy (6/03–7/04; median 
TD: 5 Gy). Median age was 52 years (27–71), median follow-up 20 months (4–76). Totally 88 regions were treated, 49 with 1 Gy, 
39 with 0.5 Gy SD. Eight different symptoms were scored from 0 (absent) –3 (severe), giving a possible sum score of 0–24. Pa-
tients’ rating of RT result was also documented (worse/stable/better/complete remission).
Results: The sum score was 15 (6–23) before RT, 2 (0–16) at the end of RT, and 1 (0–21) at last follow-up, respectively. The 
improvement was highly significant in both treatment regimens. Better or complete remission by the patients were reported in 
44 and 39 (= 83 out of 88) localisations, that was often stable during the follow-up. 5 (6%) regions in 3 (11%) patients didn’t 
benefit from RT. 
Conclusion: RT reveals excellent results in palmo-plantar eczema or psoriasis. We recommend a SD of 0.5 Gy twice a week up to 
a TD of 4–5 Gy. 
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Langzeitergebnisse der Radiotherapie bei Patienten mit palmoplantaren Ekzemen oder Psoriasis 
Hintergrund und Ziel: Die Radiotherapie (RT) ist eine etablierte Therapiemethode bei therapierefraktären palmoplantaren Ekze-
men und Psoriasis (Tabelle 1), trotz fehlender Evidenz betreff Langzeitresultaten. Des Weiteren bleibt die optimale Dosierung 
unklar. Wir stellen die Resultate der RT mit zwei verschiedenen Dosierungskonzepten (Einzel-/Gesamtdosis, ED/GD) vor. 
Patienten und Methodik: 28 konsekutive Patienten mit therapierefraktären Ekzemen oder Psoriasis der Hände und/oder der 
Füße wurden zwei Mal pro Woche entweder mit ED 1 Gy (von Juni 1998 – Mai 2003; mediane GD: 12 Gy) oder mit ED 0,5 Gy (von 
Juni 2003 – Juli 2004; mediane GD: 5 Gy) bestrahlt. Das Alter der Patienten betrug median 52 Jahre (27–71), die Beobachtungs-
zeit median 20 Monate (4–76). Insgesamt wurden 88 Regionen bestrahlt, 49 mit ED 1 Gy und 39 mit ED 0,5 Gy. Acht verschiedene 
Symptome wurden jeweils zwischen 0 (symptomfrei) und 3 (schwer) eingestuft (Tabelle 2), was in einem Summen-Score von 0 bis 
24 resultierte. Ebenfalls wurde die Beurteilung des Therapieergebnisses durch die Patienten selbst (schlechter, unverändert, 
besser, komplette Remission) dokumentiert.
Ergebnisse: Der Summen-Score vor der RT betrug median 15 (6–23), bei RT-Abschluss 2 (0–16) und bei der letzten Nachkontrol-
le 1 (0–21) (Tabelle 3, Abbildung 1). Ein hochsignifikanter Unterschied zum Ausgangsbefund konnte für beide Behandlungssche-
mata dokumentiert werden (Tabelle 4). In 44 bzw. 39 (= 83 von 88) Lokalisationen haben die Patienten das Ergebnis bei RT-Ab-
schluss als besser bzw. als komplette Remission bezeichnet; dies hielt im weiteren Verlauf häufig an (Abbildungen 2 und 3). In 5 
(6%) Lokalisationen bei 3 (11%) Patienten war keine Verbesserung nach der Radiotherapie zu verzeichnen. 
Schlussfolgerung: Die Ergebnisse der Bestrahlung bei palmoplantaren Ekzemen und Psoriasis sind für beide Behandlungs-
schemata ausgezeichnet. Wir empfehlen eine ED von 0,5 Gy und eine GD von 4–5 Gy. 
Schlüsselwörter:  Palmoplantare Ekzeme · Psoriasis · Radiotherapie · Dosis 
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Introduction
Eczema and psoriasis are common skin disorders affecting 
1–5% of the adult population [17, 20]. Due to an often chronic 
natural history they represent a major cause of morbidity and 
disability [18, 20, 30]. In general there is no evidence from 
large, prospective randomised studies with long-term follow-
up for the 3 current treatment options – topical corticoste-
roids, topical coal tar and PUVA/UVB [3, 20, 30]. For thera-
py-refractory disease radiotherapy (RT) is well accepted [22], 
despite insufficient evidence for a comparative advantage of 
irradiation compared to the above mentioned treatment mo-
dalities. 
Randomized controlled trials regarding RT (6 in palmar 
eczema, 1 in plantar eczema and 2 for palmo-plantar psoriasis, 
Table 1) do not fulfill current standards: they included low 
number of patients (14–30 patients) with a follow-up of only 
1.3–6 months. Furthermore, the optimal irradiation dose is un-
known [10, 28].
The aim of this study was to evaluate the clinical long-
term outcome of RT with two different treatment policies ac-
cording to RT dose for patients with palmar and/or plantar 
eczema or psoriasis.
Patients and Methods
Between June 1998 and July 2004 34 consecutive patients were 
referred for RT from the Department of Dermatology due to 
chronic palmar and/or plantar eczema or psoriasis. 6 patients 
were not treated due to patient refusal. 28 patients (14 female; 
14 male) received radiotherapy (RT) for eczema (n = 22) or 
psoriasis (n = 6). Median age was 52 years (range: 27–71 years). 
Before the referral to our institute patients were treated with 
different regimens. The median disease duration before RT 
was 84 months (range: 7–243 months).
The median number of regions to be irradiated was 2 
(range: 1–10 regions) per patient, resulting in totally 88 re-
gions. All patients received orthovoltage irradiation either 
with 43 kV (with Dermopan in 11 patients) or 50 kV (with 
Therapax in 17 patients). 
Until May 2003 a single dose of 1 Gy (Dmax) twice a week 
was used for 49 regions, and the median total dose was 12 Gy 
(range: 7–13 Gy), whereas afterwards our treatment policy 
was changed and consisted of 0.5 Gy (Dmax) single dose twice 
a week for 39 regions up to a median total dose of 5 Gy 
(range: 2.5–8 Gy). Examinations were always done by both, 
a radiation oncologist (MN) and dermatologist (PI) accord-
ing to a prospectively designed score, which was generated 
due to following symptoms (Table 2): itching, pain, impair-
ment of mobility, psychosocial burden, redness, hyperkera-
tosis, scaling and cracks. Each symptom was divided into 4 
groups ranging from none (grade 0) up to severe (grade 3) in 
addition to mild or moderate symptoms (grade 1 or 2, respec-
tively). Each treatment location (n = 88) was analyzed ac-
cording to above mentioned categories with a score from 
0–3, giving a sum score for all eight parameters (minimum 
to maximum score points: 0–24). Complete remission was 
defined by a sum score of 0. 
Table 1. Randomized controlled trials in palmo-plantar eczema and psoriasis. 
Tabelle 1. Randomisierte kontrollierte Studien zur Radiotherpie der palmoplantaren Ekzeme und Psoriasis. 
Authors No. of  Follow-up Experimental and Results
 Patients  in months* control treatments
Eczema
Fairris GM, et al. 1985 [6] 25 3 50 kV, 3 × 1 Gy vs. 10 kV, 3 × 3 Gy  X-ray statistically significant better than grenz- 
   every 3 weeks ray 3, 6 and 12 weeks after start of treatment  
    not more 18 weeks 
Fairris GM, et al. 1984 [7] 14 3 50 kV, 3 ×1 Gy vs. 3 × placebo every 3 weeks RT better than placebo but not significant 
Fairris GM, et al. 1984 [9] 23 3 50 kV, 3 × 1 Gy vs. 3 × placebo every 3 weeks RT significant better than placebo, especially  
    after 6 and 9 weeks 
Lindelof B, et al. 1987 [16] 24 1.3 10 kV, 6 × 3 Gy vs. 6 × placebo every week Grenz-ray better than placebo after 5 weeks 
King CM, et al. 1984 [14] 15 6 45 kV, 3 × 1 Gy vs. 3 × placebo every week RT better significant after 1 month, but no more 
    significant after 3 and 6 months
Sheehan-Dare RA, et al.  21 3 50 kV, 3 × 0.9 Gy every 3 weeks vs.  RT significant better in the 6th week of treatment
1989 [27]    photochemotherapy for 6 weeks, 3 × a week but no more 3 and 12 weeks after treatment 
Cartwright PH, et al.  unknown 3 10 kV, 3 × 3 Gy vs. 3 × placebo, every 3 weeks Grenz-ray not better than placebo
1987 [2] (less than 
 30)
Psoriasis
Fairris GM, et al. 1984 [8] 6 3 50 kV, 3 × 1 Gy vs. placebo every 3 weeks Only one patient benefit, RT has little or no 
    therapeutic effect upon palmoplantar psoriasis 
Lindelof B, et al. 1990 [15] 15 1.7 10 kV, 6 × 4 Gy vs. placebo every week RT significant better than placebo but the 
    response was moderate 
*Time between the end of treatment and last control 
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The score for each symptom as well as the sum score was 
documented at baseline before RT, at the end of RT and at 
last follow-up. 
Statistical comparisons between the situation before irra-
diation and at last follow-up were done by the Mann-Whitney 
U-test. In addition patients were asked about their personal 
rating of RT response according to four possible groups: worse, 
stable, better and no symptoms (= complete remission). 
The median follow-up (defined from the end of RT till 
last control) was 20 months (range: 4–76 months). 
Results 
As shown in Figure 1 and in Table 3 all 
patients were symptomatic before RT, 
most of them with a high sum score (me-
dian: 15; range: 6–23). Most common 
grade 3 symptoms were severe itching 
(69% of all regions) and intense pain 
(73% of all regions): Severe impairment 
of mobility and severe psychosocial bur-
den were reported in 42% and 38%. 
Other symptoms like redness, hyperker-
atosis, scaling and cracks were reported 
in 20% as grade 3. Only 5% of regions 
were free of pain, other symptoms were 
absent in 6–26%. 
At the end of RT the median sum 
score was 2 (range: 0–16), and 20% ex-
perienced complete remission (sum 
score of 0).
Table 2. Score of evaluated symptoms. 
Tabelle 2. Einteilung evaluierter Krankheitssymptome. 
Score Grade 0 Grade 1 Grade 2  Grade 3
Score-points 0 1 2 3
Itching  None Rare and/or mild Often but mild  Allways and
   or rare but  intense
   intense 
Pain None Only by movement Spontaneous,  Spontaneous, 
   analgetics not  intense, analgetics
   necessary necessary
Impairment of None Mild Moderate, no work Severe, work 
mobility   disability, no  disability, relieving
   relieving posture posture
Psychosocial burden None Mild Moderate Severe
Redness None Mild Moderate Severe
Hyperkeratosis None Mild Moderate Severe
Scaling None Mild Moderate Severe
Cracks None Few, small, without  Moderate, between Many, deep, 
  bleeding 1 and 3 with bleeding
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Figure 1. Severity of symptoms before and after radiotherapy and at last control (see also Table 2).
Abbildung 1. Ausprägung der einzelnen Symptome vor und nach Radiotherapie sowie bei der letzten Nachkontrolle (siehe auch Tabelle 2).
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At last control the median sum 
score was 1 (range: 0–21), and 36% had 
complete remission (Table 3, Figures 2 
and 3). RT had a similar impact on each 
symptom (Figure 1). The differences 
compared to the situation before RT 
were highly significant (Table 3). 
There was no marked difference be-
tween single doses of 0.5 Gy (median 
total dose of 5 Gy) and 1 Gy (median to-
tal dose of 12 Gy): the median sum score 
for both groups was 15 vs. 14 before RT, 
2 vs. 2 at the end of RT and 0 vs. 2 at last 
control, respectively (Table 4). A signifi-
cant improvement could be documented 
in both treatment groups. 
According to patients’ reports ini-
tial symptoms were rated stable at the 
end of RT in 5 out of 88 regions (3 out of 
28 patients), better in 44 regions, and 39 
regions were reported as complete re-
mission. At last follow-up complete re-
mission was reported for 32 regions (28 
out of the “complete remission” group 
and 4 out of the “better” group at the 
end of RT). All 5 with stable symptoms 
at the end of RT remained unchanged at 
last follow-up (Figure 1). No region was 
rated worse by the patients, neither at 
the end of RT nor at last control. 
We did not see any side effects due 
to radiotherapy. 
Discussion 
There is a long history for irradiation in 
benign diseases [25, 29]. First treatments 
by RT for chronic eczema and psoriasis 
were described in 1898 [11, 24]. Over de-
cades the indication for RT in benign 
diseases was well accepted. In 1925 more 
pages were given to describing RT indi-
cations of various benign diseases than 
for cancer in the most comprehensive 
textbook for RT of that time [19]. The 
use of RT has decreased considerably as 
reports about carcinogenesis due to ion-
izing irradiation [1, 4] and new and better 
systemic and topical treatments have be-
come available. However, e.g. in eczema 
and psoriasis of palms and soles RT is 
still a valid option after other therapeu-
tic methods have failed [22]. 
The efficacy of RT in chronic ecze-
ma and psoriasis is supported by the re-
Table 3. Severity of symptoms for all 88 localisations before and after radiotherapy and at last 
control (score-points according to Table 2). 
Tabelle 3. Ausprägung der einzelnen Symptome für alle 88 Lokalisationen vor und nach Radio-
therapie sowie bei der letzten Nachkontrolle (Score-Punkte gemäß Tabelle 2). 
Symptom Score  Before irradiation End of irradiation Last control p-value*
 points n = 88 % n = 88 % n = 88 %
Itching 0  8  9 58 66 56 64 < 0.0001
 1  4  5 17 19 12 14
 2 15 17  2  2  3  3
 3 61 69 11 13 17 19
Pain 0  4  5 66 75 65 74 < 0.0001
 1 12 14  7  8  4  5
 2  8  9 11 13  1  1
 3 64 73  4 5 18 20
Impairment  0 23 26 67 76 69 78 < 0.0001
of mobility 1 12 14  6  7  2  2
 2 16 18 11 13  5  6
 3 37 42  4  5 12 14
Psychosocial  0 13 15 71 81 64 73 < 0.0001
burden 1 17 19  4  5  7  8
 2 25 28  9 10  3  3
 3 33 38  4  5 14 16
Redness 0  4  5 34 39 55 63 < 0.0001
 1 42 48 42 48 29 33
 2 26 30 12 14  1  1
 3 16 18  0  0  3  3
Hyperkeratosis 0 20 23 50 57 64 73 < 0.0001
 1 21 24 35 40 17 19
 2 33 38  3  3  5  6
 3 14 16  0  0  2  2
Scaling 0  5  6 45 51 49 56 < 0.0001
 1 35 40 40 45 33 38
 2 32 36  3  3  4  5
 3 16 18  0  0  2  2
Cracks 0 17 19 64 73 72 82 < 0.0001
 1 29 33 21 24 10 11
 2 24 27  3  3  4  5
 3 18 20  0  0  2  2
*p-values are given for each symptom at last control compared to the situation before irradiation.
Figure 2. Chronic hand eczema in a 67-year-old woman before (a) and 8 month after radio-
therapy (b): total dose 4 Gy in eight fractions, delivered twice per week, 50 kV. 
Abbildung 2. Chronisches Handekzem bei einer 67-jähriger Patientin, vor (a) und 8 Monate 
nach Radiotherapie (b): Gesamtdosis 4 Gy in acht Fraktionen, zweimal pro  Woche, 50 kV. 
a b
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sults of randomized trials, all of them were performed in the 
eighties (Table 1). According to current standards they hard-
ly fulfill criteria for evidence-based medicine [3, 20, 30]. They 
included low numbers of patients and follow-up was only 
5 weeks to 6 months (median 4 months). Therefore outcome 
in the mid or long term is unknown. Severity-scores for symp-
toms were different and simplified encompassing several 
symptoms. Due to the absence of accepted severity-scores in 
both eczema and psoriasis [5, 20, 30, 31] a comparison of trials 
is difficult. Regarding RT single doses of 0.9 Gy – 4 Gy and 
total doses of 2.7 Gy – 24 Gy were used 
in these trials. Unfortunately newer data 
are lacking. 
Our study revealed several interest-
ing findings: We have scored 8 different 
symptoms, and there was a marked re-
duction of severity in each symptom at 
the end of RT, which was quite stable till 
last follow-up. These improvements 
were highly significant.
Complete remission (CR) and im-
provement of symptoms were seen for a 
high proportion of treated areas at the 
end of RT according to patients’ rating. 
CR and improvement were documented 
for almost all regions (39 + 44 = 83 out of 
88), which remained stable in 68 areas 
(32 with CR and 36 with improvement) 
at last follow-up. On the other hand, the 
remaining 5 regions (3 patients) without 
change at the end of RT showed no im-
provement also during the follow-up. 
Doctors’ rating revealed also excel-
lent results: CR (sum-score: 0) or nearly 
CR (sum-score: 1–4) was documented 
for 18 + 48 = 66 out of 88 regions at the 
end of RT, and for 32 + 31 = 63 out of 88 
regions at last follow-up. 
We could not see major differences 
between lower and higher doses of RT, 
both treatment schedules revealed high-
ly significant rates of improvement. This 
is in accordance with the literature on ir-
radiation in benign diseases [13, 23, over-
views in 10 and 28]. The only systematic 
dose-finding study was performed on 
more than 500 localisations with eczema 
or psoriasis, and there was no difference 
between 0.6 Gy, 0.8 Gy and 1 Gy [10]. In 
a recent overview by Panizzon [22] single 
doses of 0.3 Gy to 1 Gy and total doses of 
3 Gy to 12 Gy are recommended for in-
flammatory diseases including eczema 
and psoriasis. 
The excellent results are in part dif-
ferent in comparison with previous pub-
lished studies summarized in Table 1. 
There is no obvious reason for that, how-
ever findings among randomized studies 
Table 4. Changes of sum-score for all 88 localisations (bold) and for the subgroups treated with 
a single dose (SD) of 0.5 Gy and 1.0 Gy. 
Tabelle 4. Änderungen des Summen-Scores bezogen auf alle 88 bestrahlten Lokalisationen 
(fett) mit Berücksichtigung der Untergruppen mit Einzeldosen (SD) von 0.5 Gy bzw. 1 Gy. 
Sum- Before irradiation End of irradiation Last control
score n = 88  n = 88  n = 88
 SD: 0.5 Gy SD: 1.0 Gy SD: 0.5 Gy SD: 1.0 Gy SD: 0.5 Gy SD: 1.0 Gy
 n = 39 n = 49 n = 39 n = 49 n = 39 n = 49
0       0       18       32
 0 0 11 7 21 11
1–4       0       48       31
 0 0 21 27 7 24
5–8       4        7        3
 4 0 1 6 0 3
9–12      22        8       11
 7 15 3 5 5 5
13–16      30        7        9
 14 16 3 4 6 3 
17–20      24        0        1
 8 16 0 0 0 1
21–24       8        0        2
 6 2 0 0 0 2
Median   15 (6–23)    2 (0–16)     1 (0–21)
        p < 0.0001*
(range) 15 (6–23) 14 (9–21) 2 (0–16) 2 (0–15) 0 (0–16) 2 (0–21)
     p < 0.0001* p < 0.0001*
*compared to the situation before irradiation
Figure 3. Palmoplantar psoriasis in a 52-year-old man before (a) and 14 months after radio-
therapy (b): total dose 6 Gy in twelve fractions, delivered twice per week, 50 kV.
Abbildung 3. Psoriasis palmoplantaris bei einem 52-jährigen Patienten, vor (a) und 14 Monate 
nach Radiotherapie (b): Gesamtdosis 6 Gy in zwölf Fraktionen, zweimal pro Woche, 50 kV.
a b
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are also inconsistent. A well conducted randomized study 
should be performed to show that radiotherapy might be an 
ideal treatment option for resistant cases to topical and physi-
cal treatments. Similar to other nonmalignant diseases [12, 21, 
26] undertaking of a pattern of care study would be also desir-
able in palmoplantar eczema and psoriasis. It would be inter-
esting to see how many radiotherapy centers actually treat 
chronic palmo-plantar eczema or psoriasis, and with which 
technique and dose. The potential risk of irradiation of a be-
nign, non-life-threatening disease must be recognised. How-
ever, regarding the very low risk of radiation-induced cancer 
RT may be considered if other methods have not succeeded 
and if the consequences of no further treatment are unaccept-
able for the patient. 
Conclusion 
Topical steroids are the mainstay of the pharmacological 
treatment of palmo-plantar eczema and psoriasis. For patients 
with otherwise therapy-refractory eczema or psoriasis RT of-
fers high rates of improvement or complete remission, which 
can last several years. RT should be taken into consideration 
in these patients. Both treatment regimens, low and higher 
dose irradiation, had highly significant improvement rates. 
Therefore, we propose a single dose of 0.5 Gy, twice a week, to 
a total dose of max. 5 Gy.
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